Gadopentetate Dimeglumine
drugOn this page
Also known as Acide gadopentetiqueAcido gadopenteticoDimeglumine gadopentetateGadopentate dimeglumineGadopentetic acidGadopentetic acid dimeglumine saltMagnevistMeglumine gadopentetateSH L 451 ASH-L 451 ASHL-451A
Summary
Gadopentetate Dimeglumine (CHEMBL1200431) is an approved small molecule (ATC V08CA01); indicated across 1 condition including neoplasm.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Small molecule
- ATC class: V08CA01
- Indications: 1 condition
- Clinical trials: 18
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1200431 |
| Name | Gadopentetate Dimeglumine |
| Type | Small molecule |
| Max phase | 4 |
| ATC | V08CA01 |
Also known as: Acide gadopentetique, Acido gadopentetico, Dimeglumine gadopentetate, Gadopentate dimeglumine, Gadopentetate dimeglumine, Gadopentetic acid, Gadopentetic acid dimeglumine salt, Magnevist, Meglumine gadopentetate, SH L 451 A, SH-L 451 A, SHL-451A
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
1 indication (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| neoplasm | 2 | MONDO:0005070 | MONDO:0004992 |
Clinical trials
Total trials: 18.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 9 |
| PHASE3 | 4 |
| PHASE2 | 4 |
| PHASE4 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01956409 | PHASE4 | UNKNOWN | Proton MR Spectroscopy and 18F-Fluorocholine PET for Breast Cancer Diagnosis |
| NCT00395460 | PHASE3 | COMPLETED | Efficacy and Safety Study to Evaluate Gadavist (Gadobutrol) as Contrast Agent in Magnetic Resonance Imaging (MRI) of Brain or Spine Diseases in Chinese Patients |
| NCT00408083 | PHASE3 | COMPLETED | Crossover Study With MultiHance vs a Comparator for Peripheral MRA |
| NCT00486473 | PHASE3 | COMPLETED | Multihance Versus Magnevist in Breast MRI |
| NCT01260636 | PHASE3 | COMPLETED | Crossover Comparison of Two Gadolinium Contrast Agents for Use With MRA of Carotid, Renal and Peripheral Arteries |
| NCT00019604 | PHASE2 | TERMINATED | Radiofrequency Ablation in Treating Patients With Unresectable Primary or Metastatic Liver Cancer |
| NCT00043017 | PHASE2 | COMPLETED | Magnetic Resonance Imaging in Women Receiving Chemotherapy for Stage III Breast Cancer |
| NCT00373152 | PHASE2 | WITHDRAWN | MRI in Predicting Tumor Reponse After Radiofrequency Ablation in Women With Invasive Breast Cancer |
| NCT00375830 | PHASE2 | COMPLETED | Combined 18F-NaF/18F-FDG PET/MRI for Detection of Skeletal Metastases |
| NCT00004936 | Not specified | COMPLETED | MRI and CT Scans to Evaluate Invasive Cervical Cancer Before Treating Patients |
| NCT00005790 | Not specified | WITHDRAWN | Perfusion Magnetic Resonance Imaging in Measuring the Growth of Blood Vessels in Newly Diagnosed Brain Tumors |
| NCT00033397 | Not specified | COMPLETED | Diagnostic Procedures in Women With Locally Advanced Breast Cancer Who Are Receiving Chemotherapy Before Breast Cancer Surgery |
| NCT00060008 | Not specified | TERMINATED | Fludeoxyglucose F 18 Positron Emission Tomography and Magnetic Resonance Perfusion Imaging in Patients With Neurofibromatosis 1 and Plexiform Neurofibroma |
| NCT00677963 | Not specified | COMPLETED | Contrast-enhanced Ultrasound (CE-US) and Magnetic Resonance Imaging (MRI): Evaluating Plaque Neovascularisation |
| NCT01416740 | Not specified | WITHDRAWN | A Comparison of Indirect and Direct MR Arthrography of the Shoulder Using Arthroscopic Correlation |
| NCT02371798 | Not specified | WITHDRAWN | Unilateral Meniere Disease: Can Double Dose Gadolinium and Delayed Imaging Make the Diagnosis? |
| NCT02967380 | Not specified | TERMINATED | Gadobutrol Versus Gadopentetate Dimeglumine or Gadobenate Dimeglumine Before DCE-MRI in Diagnosing Patients With Multiple Sclerosis, Grade II-IV Glioma, or Brain Metastases |
| NCT03910114 | Not specified | COMPLETED | Gadolinium-Based-Contrast-Agents (GBCA) Enhancement During MR Urography |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.